CN111233834B - FAK-targeting compound and markers thereof, and preparation methods and applications of FAK-targeting compound and markers - Google Patents
FAK-targeting compound and markers thereof, and preparation methods and applications of FAK-targeting compound and markers Download PDFInfo
- Publication number
- CN111233834B CN111233834B CN202010157272.8A CN202010157272A CN111233834B CN 111233834 B CN111233834 B CN 111233834B CN 202010157272 A CN202010157272 A CN 202010157272A CN 111233834 B CN111233834 B CN 111233834B
- Authority
- CN
- China
- Prior art keywords
- compound
- reaction
- solution
- fak
- ethyl acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 169
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 230000008685 targeting Effects 0.000 claims abstract description 22
- 230000002285 radioactive effect Effects 0.000 claims abstract description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 144
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 84
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 78
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 63
- 238000006243 chemical reaction Methods 0.000 claims description 62
- 238000000034 method Methods 0.000 claims description 62
- 238000003756 stirring Methods 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 30
- 239000000706 filtrate Substances 0.000 claims description 22
- 239000000047 product Substances 0.000 claims description 22
- 238000010898 silica gel chromatography Methods 0.000 claims description 21
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 20
- 239000002243 precursor Substances 0.000 claims description 20
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 18
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 16
- WLKUSVNHZXUEFO-UHFFFAOYSA-N 4-fluoro-2-methoxy-1-nitrobenzene Chemical compound COC1=CC(F)=CC=C1[N+]([O-])=O WLKUSVNHZXUEFO-UHFFFAOYSA-N 0.000 claims description 15
- 238000002390 rotary evaporation Methods 0.000 claims description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 14
- 239000011541 reaction mixture Substances 0.000 claims description 14
- 238000010438 heat treatment Methods 0.000 claims description 13
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 claims description 12
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 claims description 12
- 229940127204 compound 29 Drugs 0.000 claims description 12
- 239000007791 liquid phase Substances 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 11
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 claims description 10
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 10
- 229940126543 compound 14 Drugs 0.000 claims description 10
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
- 229940126214 compound 3 Drugs 0.000 claims description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 9
- GIKMWFAAEIACRF-UHFFFAOYSA-N 2,4,5-trichloropyrimidine Chemical compound ClC1=NC=C(Cl)C(Cl)=N1 GIKMWFAAEIACRF-UHFFFAOYSA-N 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 claims description 7
- 229940125833 compound 23 Drugs 0.000 claims description 7
- 230000014759 maintenance of location Effects 0.000 claims description 7
- 238000000163 radioactive labelling Methods 0.000 claims description 7
- AUFVJZSDSXXFOI-UHFFFAOYSA-N 2.2.2-cryptand Chemical compound C1COCCOCCN2CCOCCOCCN1CCOCCOCC2 AUFVJZSDSXXFOI-UHFFFAOYSA-N 0.000 claims description 6
- 238000007664 blowing Methods 0.000 claims description 6
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 claims description 5
- SIKXIUWKPGWBBF-UHFFFAOYSA-N 5-bromo-2,4-dichloropyrimidine Chemical compound ClC1=NC=C(Br)C(Cl)=N1 SIKXIUWKPGWBBF-UHFFFAOYSA-N 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 5
- 238000006555 catalytic reaction Methods 0.000 claims description 5
- 238000003682 fluorination reaction Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000010534 nucleophilic substitution reaction Methods 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- UUOLETYDNTVQDY-UHFFFAOYSA-N 2-chloro-3-nitropyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1Cl UUOLETYDNTVQDY-UHFFFAOYSA-N 0.000 claims description 4
- XNRDLSNSMTUXBV-UHFFFAOYSA-N 2-fluoroethyl 4-methylbenzenesulfonate Chemical compound CC1=CC=C(S(=O)(=O)OCCF)C=C1 XNRDLSNSMTUXBV-UHFFFAOYSA-N 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- -1 FAK compound Chemical class 0.000 claims description 4
- 239000003480 eluent Substances 0.000 claims description 4
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims description 4
- 239000003208 petroleum Substances 0.000 claims description 4
- 239000012071 phase Substances 0.000 claims description 4
- WHPFEQUEHBULBW-UHFFFAOYSA-N 2,4-dichloro-5-fluoropyrimidine Chemical compound FC1=CN=C(Cl)N=C1Cl WHPFEQUEHBULBW-UHFFFAOYSA-N 0.000 claims description 3
- ZTHHRSBDBPCCMZ-UHFFFAOYSA-N 2,4-dichloro-5-methoxypyrimidine Chemical compound COC1=CN=C(Cl)N=C1Cl ZTHHRSBDBPCCMZ-UHFFFAOYSA-N 0.000 claims description 3
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 claims description 3
- 229940125904 compound 1 Drugs 0.000 claims description 3
- 229940125898 compound 5 Drugs 0.000 claims description 3
- 238000002386 leaching Methods 0.000 claims description 3
- JYGWVCOFTZZSGS-UHFFFAOYSA-N methylsulfonylmethanamine Chemical compound CS(=O)(=O)CN JYGWVCOFTZZSGS-UHFFFAOYSA-N 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 239000012312 sodium hydride Substances 0.000 claims description 2
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 claims 1
- ZYNMJJNWXVKJJV-UHFFFAOYSA-N propan-2-yloxybenzene Chemical compound CC(C)OC1=CC=CC=C1 ZYNMJJNWXVKJJV-UHFFFAOYSA-N 0.000 claims 1
- 238000007789 sealing Methods 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 45
- 230000000694 effects Effects 0.000 abstract description 18
- 230000005764 inhibitory process Effects 0.000 abstract description 17
- 241000699670 Mus sp. Species 0.000 abstract description 12
- 229940079593 drug Drugs 0.000 abstract description 11
- 239000003814 drug Substances 0.000 abstract description 11
- 238000009826 distribution Methods 0.000 abstract description 9
- 238000000338 in vitro Methods 0.000 abstract description 9
- 239000003550 marker Substances 0.000 abstract description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract description 6
- 101000878536 Homo sapiens Focal adhesion kinase 1 Proteins 0.000 abstract description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 102
- 239000000243 solution Substances 0.000 description 65
- 239000007787 solid Substances 0.000 description 47
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 43
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 43
- 238000005160 1H NMR spectroscopy Methods 0.000 description 35
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 33
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 32
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 24
- 238000003786 synthesis reaction Methods 0.000 description 16
- 238000000605 extraction Methods 0.000 description 15
- KAFZOLYKKCWUBI-HPMAGDRPSA-N (2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-3-amino-2-[[(2s)-2-[[(2s)-2-(3-cyclohexylpropanoylamino)-4-methylpentanoyl]amino]-5-methylhexanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CCC(C)C)C(=O)N[C@@H](CN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(N)=O)C(=O)CCC1CCCCC1 KAFZOLYKKCWUBI-HPMAGDRPSA-N 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 229940125810 compound 20 Drugs 0.000 description 11
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 238000006911 enzymatic reaction Methods 0.000 description 10
- 239000002287 radioligand Substances 0.000 description 10
- 108091000080 Phosphotransferase Proteins 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 102000020233 phosphotransferase Human genes 0.000 description 9
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 8
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 8
- 229940125797 compound 12 Drugs 0.000 description 8
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 7
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 7
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 7
- 229940125936 compound 42 Drugs 0.000 description 7
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 6
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 229940126142 compound 16 Drugs 0.000 description 6
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 5
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 5
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 5
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 5
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 5
- 229940127007 Compound 39 Drugs 0.000 description 5
- 229940125758 compound 15 Drugs 0.000 description 5
- 229940125877 compound 31 Drugs 0.000 description 5
- 238000013399 early diagnosis Methods 0.000 description 5
- 239000012217 radiopharmaceutical Substances 0.000 description 5
- 229940121896 radiopharmaceutical Drugs 0.000 description 5
- 230000002799 radiopharmaceutical effect Effects 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- FOLCUFKJHSQMEL-BIXPGCQOSA-N (4-butylcyclohexyl) N-[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]pentan-2-yl]carbamate Chemical compound CCCCC1CCC(CC1)OC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@@H]2CCNC2=O)C=O FOLCUFKJHSQMEL-BIXPGCQOSA-N 0.000 description 4
- UXKLQDCALAWFIU-VKNDCNMPSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-tetradecoxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@H](O)[C@H](C(O2)(C(O)=O)C(O)(C(O1)C(O)=O)C(O)=O)OCCCCCCCCCCCCCC)C1=CC=CC=C1 UXKLQDCALAWFIU-VKNDCNMPSA-N 0.000 description 4
- VGNCBRNRHXEODV-XXVHXNRLSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-6-dodecoxy-4,7-dihydroxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@H](O)[C@H](C(O2)(C(O)=O)C(O)(C(O1)C(O)=O)C(O)=O)OCCCCCCCCCCCC)C1=CC=CC=C1 VGNCBRNRHXEODV-XXVHXNRLSA-N 0.000 description 4
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 4
- SJSOFNCYXJUNBT-UHFFFAOYSA-N 3,4,5-trimethoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC(OC)=C1OC SJSOFNCYXJUNBT-UHFFFAOYSA-N 0.000 description 4
- BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 229940127573 compound 38 Drugs 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 3
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 3
- OMBVEVHRIQULKW-DNQXCXABSA-M (3r,5r)-7-[3-(4-fluorophenyl)-8-oxo-7-phenyl-1-propan-2-yl-5,6-dihydro-4h-pyrrolo[2,3-c]azepin-2-yl]-3,5-dihydroxyheptanoate Chemical compound O=C1C=2N(C(C)C)C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C=3C=CC(F)=CC=3)C=2CCCN1C1=CC=CC=C1 OMBVEVHRIQULKW-DNQXCXABSA-M 0.000 description 3
- JTLAIKFGRHDNQM-UHFFFAOYSA-N 1-bromo-2-fluoroethane Chemical compound FCCBr JTLAIKFGRHDNQM-UHFFFAOYSA-N 0.000 description 3
- QXHDYMUPPXAMPQ-UHFFFAOYSA-N 2-(4-aminophenyl)ethanol Chemical compound NC1=CC=C(CCO)C=C1 QXHDYMUPPXAMPQ-UHFFFAOYSA-N 0.000 description 3
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 3
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 3
- 241001251200 Agelas Species 0.000 description 3
- 229940126657 Compound 17 Drugs 0.000 description 3
- 229940126639 Compound 33 Drugs 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- KIMWOULVHFLJIU-UHFFFAOYSA-N N-Methylanthranilamide Chemical compound CNC(=O)C1=CC=CC=C1N KIMWOULVHFLJIU-UHFFFAOYSA-N 0.000 description 3
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229940125846 compound 25 Drugs 0.000 description 3
- 229940125851 compound 27 Drugs 0.000 description 3
- 229940125807 compound 37 Drugs 0.000 description 3
- 229940126540 compound 41 Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 2
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 2
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 2
- FRJJJAKBRKABFA-TYFAACHXSA-N (4r,6s)-6-[(e)-2-[6-chloro-4-(4-fluorophenyl)-2-propan-2-ylquinolin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C(\[C@H]1OC(=O)C[C@H](O)C1)=C/C=1C(C(C)C)=NC2=CC=C(Cl)C=C2C=1C1=CC=C(F)C=C1 FRJJJAKBRKABFA-TYFAACHXSA-N 0.000 description 2
- IDRUEHMBFUJKAK-UHFFFAOYSA-N 2,4-dichloro-5-(trifluoromethyl)pyrimidine Chemical compound FC(F)(F)C1=CN=C(Cl)N=C1Cl IDRUEHMBFUJKAK-UHFFFAOYSA-N 0.000 description 2
- WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical compound OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 2
- IWPZKOJSYQZABD-UHFFFAOYSA-N 3,4,5-trimethoxybenzoic acid Natural products COC1=CC(OC)=CC(C(O)=O)=C1 IWPZKOJSYQZABD-UHFFFAOYSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 2
- 101000878540 Homo sapiens Protein-tyrosine kinase 2-beta Proteins 0.000 description 2
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 2
- 101150026109 INSR gene Proteins 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- RZQVNSUDESXFIU-UHFFFAOYSA-N NCC1=CC=CC(S(Cl)(=O)=O)=C1 Chemical compound NCC1=CC=CC(S(Cl)(=O)=O)=C1 RZQVNSUDESXFIU-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 2
- 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000711955 Turkey rhinotracheitis virus Species 0.000 description 2
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940126208 compound 22 Drugs 0.000 description 2
- 229940125878 compound 36 Drugs 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000000249 desinfective effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000003966 growth inhibitor Substances 0.000 description 2
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 2
- 239000012216 imaging agent Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 238000007430 reference method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 2
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- ZVHZPFSWZWSDEN-UHFFFAOYSA-N 1-bromo-1-fluoroethane Chemical compound CC(F)Br ZVHZPFSWZWSDEN-UHFFFAOYSA-N 0.000 description 1
- DQXNTSXKIUZJJS-UHFFFAOYSA-N 2,4-dichloro-5-methylpyrimidine Chemical compound CC1=CN=C(Cl)N=C1Cl DQXNTSXKIUZJJS-UHFFFAOYSA-N 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- XQFKFYADGYYGOB-UHFFFAOYSA-N 5-ethoxy-5,6-dimethylcyclohexa-1,3-diene Chemical compound CC1(OCC)C(C=CC=C1)C XQFKFYADGYYGOB-UHFFFAOYSA-N 0.000 description 1
- 229910020323 ClF3 Inorganic materials 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 1
- 206010035603 Pleural mesothelioma Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 102000057090 human PTK2 Human genes 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a FAK-targeting compound, which has a structure shown in the following formula (I), wherein R1is-F, -Cl, -Br, -CH3or-OCH3;R2、R3、R5Are methoxy or-H respectively; r4Is composed ofOrR6is-H, -CH2CH2OH or-CH2CH2F. The invention also provides a class of radiolabeled compounds targeting FAK. The compound has excellent in-vitro FAK kinase activity inhibition effect; the radioactive marker has ideal biological distribution in S180 tumor-bearing mice. The invention also provides a preparation method of the compound and a radioactive marker thereof and application of the compound and the radioactive marker thereof in preparing tumor drugs.
Description
Technical Field
The invention relates to the field of compounds, in particular to a FAK (Focal Adhesion Kinase) targeted compound and an F-18 marker thereof, and a preparation method and application thereof.
Background
Focal Adhesion Kinase (FAK) is an non-receptor tyrosine Kinase and plays a crucial role in various links such as tumor generation, development and metastasis. FAK is highly or over-expressed in most tumor cell types, and thus, FAK is a potential tumor diagnosis target.
It is also necessary to develop radiopharmaceuticals with high specificity and high sensitivity to tumors. Over the past three decades, a number of radiopharmaceuticals have been designed and developed to image and identify the unique biochemical properties of tumor tissue. The high expression phenomenon of FAK in tumors can also be used as early diagnosis, treatment and prognosis evaluation of tumors on the level of radiopharmaceuticals.
In the prior art, some FAK small molecule inhibitors have been in clinical study on the general pharmaceutical level, as listed in table 1 below:
TABLE 1 FAK Small molecule inhibitors currently in the discovery and study stage
However, the tumor inhibition activity of these FAK small molecule inhibitors still needs to be improved. Therefore, it is necessary to develop a new FAK-targeting tumor growth inhibitor, and a good foundation is provided for the FAK-targeting drugs on the radiopharmaceutical layer.
Disclosure of Invention
The primary objects of the present invention are: a novel FAK-targeting compound is provided, which can be used as an effective tumor growth inhibitor molecule and also can be used as an inhibitor molecule of a rare disease tumor body such as pleural mesothelioma.
Another object of the present invention is to: the FAK-targeting compound provides a class of radioactive labels which can be used as an excellent tumor imaging agent for early diagnosis of tumors.
Yet another object of the present invention is to: methods of making the FAK-targeting compound and the radiolabel are presented.
Yet another object of the present invention is to: the FAK-targeting compound and the application of the radioactive marker in preparing early tumor treatment or diagnosis medicines are provided.
The above object of the present invention is achieved by the following technical solutions:
firstly, a compound targeting FAK is provided, and the structure of the compound is shown as the following formula (I):
wherein R is1is-F, -Cl, -Br, -CH3or-OCH3;R2、R3、R5Are respectively-OCH3or-H; r4Is composed ofOrR6is-H, -CH2CH2OH or-CH2CH2F。
In a preferred embodiment of the present invention, in the structure of the FAK targeting compound represented by formula (I), R2is-OCH3,R3And R5Are all H, R4Is composed ofNamely, the FAK targeting compound has the structure shown in the following formula (I-I):
wherein R is1is-F, -Cl, -Br, -CH3or-OCH3;R6is-H, -CH2CH2OH or-CH2CH2F。
More preferably, the FAK targeting compound represented by the formula (I-I) is specifically selected from any one of the following compounds:
compound 27aa, having the structure:
compound 27ba, structure:
compound 27ac, having the structure:
compound 27ae, having the structure:
compound 28ab, having the structure:
compound 29, having the structure:
in another preferred embodiment of the present invention, in the structure of the FAK targeting compound represented by formula (I), R2Is a compound of the formula-H,
wherein R is1is-F, -Cl, -Br, -CH3or-OCH3(ii) a More preferably-Cl or-Br.
More preferably, the FAK targeting compound represented by the formula (I-II) is specifically selected from any one of the following compounds:
compound 31ab, having the structure:
compound 31bb, structure:
compound 31bc, having the structure:
or,
the invention also provides a compound targeting FAK, which has the structure shown in the following formula (II):
More preferred compounds of formula (II) according to the present invention are specifically selected from any one of the following compounds:
compound 39, having the structure:
compound 43, having the structure:
or,
compound 44, having the structure:
on the basis, the invention further provides a radioactive nuclide F-18 labeled compound targeting FAK, which has a structure shown in the following formula (IV), wherein R is1is-Cl or-Br:
the invention further provides another radionuclide F-18 labeled FAK targeting compound, the structure of which is shown in the following formula (V), wherein R is1is-CH3or-Br:
the invention further provides another radionuclide F-18 labeled FAK targeting compound, the structure of which is shown in the following formula (VI), wherein R7is-Br or-CF3,R8Is composed ofOr
The invention further provides a method for preparing the FAK targeting compound and the marker thereof.
When the compound with the structure shown as the formula (I-I) is prepared, when R is6is-CH2CH2OH or-CH2CH2When F, the synthetic route is generalThe method is recorded as the first method as follows:
the preparation method comprises the following steps:
A1) stirring 2-chloro-3-nitropyridine (compound 1) and methylsulfonylmethylamine (compound 2) with equal mass in an organic solvent under an alkaline condition at 0 ℃ for reaction for 1-2h to obtain a compound 3;
A2) hydrogenating and reducing the nitro group of the compound 3 obtained in A1) into amino group under the condition of pressure catalysis at room temperature to obtain a compound 4;
A3) stirring and reacting the compound 4 obtained in the step A2) and a compound 5(2,4, 5-trichloropyrimidine, 5-bromo-2, 4-dichloropyrimidine, 5-fluoro-2, 4-dichloropyrimidine or 5-methoxy-2, 4-dichloropyrimidine) for 4-6h at the temperature of 80-90 ℃ under an alkaline condition to obtain a compound 6;
A4) introducing a piperazine structure into 4-fluoro-2-methoxynitrobenzene (compound 9), and hydrogenating under a pressurized catalytic condition to obtain a compound 17;
A5) heating the compound 6 obtained in the step A3), the compound 17 obtained in the step A4) and p-toluenesulfonic acid in an organic solution to 100-120 ℃, stirring and reacting for 4-6h, and extracting with ethyl acetate to obtain the compound with the structure shown in the formula (II).
In a preferred embodiment of the present invention, the introduction of the piperazine structure into the 4-fluoro-2-methoxynitrobenzene (compound 9) in step a4) of the first method step can be specifically accomplished by the following steps:
A41) stirring 4-fluoro-2-methoxynitrobenzene (compound 9) and 1- (2-hydroxyethyl) piperazine (compound 10) in an acetonitrile solution and triethylamine at room temperature overnight until solid is separated out, and separating to obtain solid, namely compound 11;
A42) hydrogenating and reducing the nitro group of the compound 11 obtained in the step A41) into amino group under the condition of pressurized catalysis to obtain a compound 12;
the synthetic route is as follows:
or,
A43) heating 4-fluoro-2-methoxynitrobenzene (compound 9) and piperazine (compound 13) in a1, 4-dioxane solution to 110-;
A44) stirring the compound 14 obtained in the step A43) and 1-bromo-2-fluoroethane in an acetonitrile solution and triethylamine at the temperature of 80-90 ℃ for reacting for 2-3h, and extracting to obtain a compound 15;
A45) hydrogenating the nitro group of the compound 15 obtained in the step A44) under the pressure catalysis condition to reduce the nitro group into amino group to obtain a compound 16.
The synthetic route is as follows:
when the compound with the structure shown in the formula (I-II) is prepared, the synthetic route of the invention is generally as follows, and is marked as a second method:
the preparation method comprises the following steps:
B1) stirring 3,4, 5-trimethoxybenzoic acid (compound 18) in a mixed solution of nitric acid and acetic acid at 40 ℃ for reacting for 3-4h to obtain a solid compound 19;
B2) stirring the compound 19 obtained in the step B1) and boron trichloride in an organic solvent at 40 ℃ for reacting for 4-5h, and extracting to obtain a solid compound 20;
B3) stirring the compound 20 obtained in the step B2) and 2-bromoethanol or bromofluoroethane in an organic solvent at a molar ratio of 1: 1.5-2 under an alkaline condition at 70-80 ℃ for 2-3h to obtain a compound 21;
B4) hydrogenating and reducing the nitro group of the compound 21 obtained in the step B3) into amino group under the condition of pressurized catalysis to obtain a compound 22;
B5) the compound 22 obtained in the step B4) and the compound 6 obtained in the step A3) of the method react with p-toluenesulfonic acid in an organic solution by heating to 100 ℃ and 120 ℃ for stirring for 4-6h, and the compound with the structure shown in the formula (I-II) is obtained by extraction with ethyl acetate.
The invention further provides a method for preparing the targeting FAK compound shown as the formula (II) when R is7is-Br and
the preparation method comprises the following steps:
C1) stirring and reacting 2-amino-N-methylbenzamide and 5-bromo-2, 4-dichloropyrimidine in an organic solvent at 80-90 ℃ for 4-6h under an alkaline condition to obtain a compound 8;
C2) heating compound 8 obtained from p-aminophenylethanol (compound 38) and C1) and p-toluenesulfonic acid in an organic solution to 100-120 ℃, stirring and reacting for 4-6h, and extracting with ethyl acetate to obtain a compound 39;
C3) adding triethylamine and p-toluenesulfonyl chloride into the compound 39 obtained in C2) at 0 ℃ in a dichloromethane solvent, and stirring and reacting for 2-3h at room temperature to obtain a compound 40;
C4) reacting the compound 40 obtained in C3) with tetrabutylammonium fluoride in a tetrahydrofuran solvent at 80-90 ℃ for 1-2h by stirring, and extracting with ethyl acetate to obtain a compound 43.
The invention further provides a method for preparing the targeting FAK compound shown as the formula (II) when R is7is-CF3And said R is8Is composed ofThen, the synthesis route is as follows:
the preparation method comprises the following steps:
D1) adding diisopropylethylamine and 3-aminomethyl benzenesulfonyl hydrochloride (compound 36) into tetrahydrofuran solution of 2, 4-dichloro-5-trifluoromethylpyrimidine (compound 35), and stirring at 0 deg.C for overnight reaction to obtain compound 37;
D2) heating the compound 37 obtained in the step D1) with sulfanilamide alcohol (compound 38) and p-toluenesulfonic acid in an organic solution to 100-;
D3) adding triethylamine and p-toluenesulfonyl chloride into the compound 41 obtained in the step D2) at 0 ℃ in a dichloromethane solvent, and stirring and reacting for 2-3h at room temperature to obtain a compound 42;
D4) reacting the compound 42 obtained in D3) with tetrabutylammonium fluoride in a tetrahydrofuran solvent at 80-90 ℃ for 1-2h under stirring, and extracting with ethyl acetate to obtain a compound 44.
The invention still further provides a process for preparing a radiolabeled targeted FAK compound of formula (IV) when R1When the molecular weight is-Cl or-Br, the method is marked as method five, and the synthetic route is as follows:
the method comprises the following specific steps:
E1) preparation of labeled precursor Compounds:
heating 4-fluoro-2-methoxynitrobenzene (compound 9) and piperazine (compound 13) in a1, 4-dioxane solution to 110-; catalytically hydrogenating the nitro group of compound 14 to provide compound 23; the compound 23 and the compound 6 obtained in the step A3) of the reference method and p-toluenesulfonic acid are heated to 100 ℃ and 120 ℃ in an organic solution and stirred for reaction for 4-6h, and the labeled precursor compound 29 is obtained by extraction with ethyl acetate;
E2) radiolabeling:
using Kryptofix 2.2.2./, [ 2 ]18F]KF/K2CO3Complexing said labelled precursor compound 29 obtained in step E1)18F-nucleophilic substitution fluorination to obtain the F-18 labeled targeting FAK compound with the structure shown in the formula (IV).
The invention further provides a method for preparing the radiolabeled target FA shown in the formula (V)A process for preparing a compound of K, wherein R1is-CH3or-Br, as method six, the synthetic route is as follows:
the method comprises the following specific steps:
F1) preparation of labeled precursor Compounds:
F2) radiolabeling:
using Kryptofix 2.2.2./, [ 2 ]18F]KF/K2CO3Complexing said labelled precursor compound 32 obtained in step F1)18F-nucleophilic substitution fluorination to obtain the F-18 labeled targeting FAK compound with the structure shown in the formula (V).
The invention still further provides a process for preparing a radiolabeled targeted FAK compound of formula (VI) when R is7is-Br, and R8Is composed ofThen, the synthesis route is as follows:
the method comprises the following specific steps:
G1) preparation of labeled precursor Compounds:
preparation according to the method of method three steps C1) -C3) to give the tagged precursor compound 40;
G2) radiolabeling:
using Kryptofix 2.2.2./, [ 2 ]18F]KF/K2CO3Compound step by stepStep G1) of obtaining said labelled precursor compound 4018F-nucleophilic substitution fluorination to obtain the F-18 labeled targeting FAK compound with the structure shown in the formula (VI).
The invention still further provides a method for preparing a radiolabeled targeted FAK compound of formula (VI), wherein R7is-CF3And R is8Is composed ofThen, the method is written as method eight, and the synthetic route is as follows:
the method comprises the following specific steps:
H1) preparation of labeled precursor Compounds:
preparation of tagged precursor compound 42 according to method three steps D1) -D3);
H2) radiolabeling:
using Kryptofix 2.2.2./, [ 2 ]18F]KF/K2CO3Complexing said labelled precursor Compound 42 obtained in step H1)18F-nucleophilic substitution fluorination to obtain the F-18 labeled targeting FAK compound with the structure shown in the formula (VI).
The FAK-targeting compound has excellent in-vitro FAK kinase activity inhibition effect; the radioactive marker has ideal biological distribution in S180 tumor-bearing mice.
The radioactive labeled targeting FAK compound prepared by the method has the radiochemical purity of more than 98 percent after conventional separation and purification, and shows good matching with a corresponding standard substance without radioactive labeling within the range of tolerance error and good in-vitro stability as a result of coinjection with the corresponding standard substance without radioactive labeling.
The invention further provides application of the FAK-targeting compound in preparation of tumor treatment medicines, wherein the tumor treatment medicines comprise tumor cell growth inhibition medicines and the like.
The invention further provides application of the radiolabeled targeting FAK compound in preparation of an imaging agent for early diagnosis of tumors.
Drawings
FIG. 1 is a radioligand [ 2 ]18F]28ab and F-19 standard thereof19F]HPLC co-injection analysis chromatogram of 28 ab.
FIG. 2 is a radioligand [ 2 ]18F]31bb and its F-19 standard substance [ alpha ]19F]HPLC co-injection analysis chromatogram of 31 bb.
FIG. 3 is a radioligand [ 2 ]18F]31bd and F-19 standard product thereof19F]HPLC co-injection analysis chromatogram of 31 bd.
FIG. 4 is a radioligand [ 2 ]18F]43 and F-19 Standard product thereof19F]43 HPLC co-injection analysis chromatogram.
FIG. 5 is a radioligand [ 2 ]18F]44 and its F-19 standard product19F]HPLC co-injection analysis chromatogram of 44.
FIG. 6 shows a compound [ 2 ]19F]28ab antitumor activity in S180 mouse model.
FIG. 7 shows a compound [ 2 ]19F]28ab mouse weight change in the S180 mouse model.
Detailed Description
In order to further explain the technical solution of the present invention in detail, the present invention will be further explained below by way of specific examples, but the technical solution of the present invention is not limited to the examples.
Example 1 organic Synthesis of Compound 27aa
A solution of Compound 2(20g, 183.4mmol) in DMF (300mL) was cooled to 0 ℃ on an ice bath, sodium hydride (8.8g, 220mmol, 60% in mineral oil, 1.2equiv) was added portionwise, stirring was carried out at 0 ℃ for 1h, 2-chloro-3-nitropyridine (Compound 1) (20g, 126.5mmol, 0.7equiv) was added, the temperature was slowly raised to room temperature, and stirring was continued for 5 h. After the reaction was complete, DMF was poured into 1L of water and then extracted with ethyl acetate (300mL x 3 times). The ethyl acetate layers were combined, dried over anhydrous sodium sulfate, filtered, concentrated by rotary evaporation, and separated by silica gel column chromatography (petroleum ether/ethyl acetate: 10/1 to 3/1) to give compound 3(22.2g, a tan solid, yield 75.9%); compound 3 is structurally characterized as follows:
1H NMR(400MHz,CDCl3,δppm):8.67(dd,J=1.6Hz,4.7Hz,1H),8.26-8.23(m,1H),7.47-7.44(m,1H),3.42(s,3H),3.07(s,3H).
13C NMR(400MHz,CDCl3,δppm):151.46,146.30,143.23,133.87,123.03,37.38,36.35.
ESI-HRMS m/z calcd for C7H10N3O4S+232.0387,found 232.0381[M+H]+.
a solution of compound 3(10g,43.3mmol,1equiv) in methanol (200mL) was added to the autoclave at room temperature, 10% palladium on carbon (1g,0.1equiv) was added, hydrogen was introduced to 10bar, and the reaction was carried out at room temperature for 2 hours. Palladium on carbon was filtered through celite, and the filtrate was concentrated by rotary evaporation to give compound 4(8.6g, a violet black solid, yield 99.0%); compound 4 was structurally characterized as follows:
1H NMR(400MHz,CDCl3,δppm):7.86(dd,J=2.4Hz,3.7Hz,1H),7.11-7.06(m,2H),4.27(s,2H),3.23(s,3H),3.08(s,3H).
13C NMR(400MHz,CDCl3,δppm):140.85,140.14,137.80,124.45,124.03,36.93,35.37.
ESI-HRMS m/z calcd for C7H12N3O2S+202.0645,found 202.0650[M+H]+.
to a solution of compound 4(5g,24.8mmol,1equiv) in DMF (100mL) was added 2,4, 5-trichloropyrimidine (5.4g,29.6mmol,1.2equiv), K2CO3(5.1g,37.2mmol,1.5equiv), the mixture was stirred at 90 ℃ for 5 h. After the reaction was completed, the DMF was poured into 500mL of water and then extracted with ethyl acetate (100mL × 3 times). The ethyl acetate layers were combined, dried over anhydrous sodium sulfate, filtered, concentrated by rotary evaporation, and separated by silica gel column chromatography (petroleum ether/ethyl acetate: 10/1 to 3/1) to give compound 6a (7.1g, a tan solid, yield 82.5%); compound 6a was structurally characterized as follows:
1H NMR(400MHz,CDCl3,δppm):8.79(d,J=8.2Hz,1H),8.70(s,1H),8.28(d,J=4.4Hz,2H),7.44-7.41(m,1H),3.31(s,3H),3.04(s,3H).
13C NMR(400MHz,CDCl3,δppm):157.53,156.16,154.93,144.43,143.69,132.11,130.87,124.13,114.84,37.53,34.76.
ESI-MS:m/z calcd for C11H10Cl2N5O2S-345.99,found 346.70[M-H]-.
adding 1- (2-hydroxyethyl) piperazine (compound 10) (9.1g,70.0mmol,1.2equiv) to a solution of 4-fluoro-2-methoxynitrobenzene (compound 9) (10g,58.4mmol,1equiv) in acetonitrile (200mL) at room temperature, the solution being turbid, adding triethylamine (14.8g,146.0mmol,2.5equiv), continuing stirring until the starting material is completely dissolved, the solution being orange and transparent, stirring overnight at room temperature, precipitating a solid, and collecting the solid by filtration to obtain compound 11(12.8g, yellow solid, yield 78.0%); compound 11 was structurally characterized as follows:
1H NMR(400MHz,CDCl3,δppm):7.94(d,J=9.3Hz,1H),6.39(dd,J=2.2Hz,9.3Hz,1H),6.28(d,J=2.0Hz,1H),3.90(s,3H),3.66(t,J=5.2Hz,2H),3.40(t,J=4.9Hz,4H),2.64(t,J=5.0Hz,4H),2.60(t,J=5.3Hz,2H).
13C NMR(400MHz,CDCl3,δppm):155.93,155.22,129.17,128.39,105.13,96.71,59.03,57.56,55.85,52.05,46.74.
ESI-HRMS m/z calcd for C13H20N3O4 +282.1448,found 282.1451[M+H]+.
a solution of compound 11(10g,35.5mmol,1equiv) in methanol (200mL) was added to the autoclave at room temperature, 10% palladium on carbon (1g,0.1equiv) was added, hydrogen was introduced to 10bar, and the reaction was carried out at room temperature for 2 hours. Palladium on carbon was filtered through celite, and the filtrate was concentrated by rotary evaporation to give compound 12(8.8g, a violet black solid, yield 99.0%); compound 12 was structurally characterized as follows:
1H NMR(400MHz,CDCl3,δppm):6.66(d,J=8.3Hz,1H),6.51(d,J=2.2Hz,1H),6.42(dd,J=2.3Hz,8.3Hz,1H),3.83(s,3H),3.67(t,J=5.2Hz,2H),3.09(t,J=4.7Hz,4H),2.70(t,J=4.9Hz,4H),2.60(t,J=5.3Hz,2H).
13C NMR(400MHz,CDCl3,δppm):147.76,144.61,129.96,115.2,109.20,102.07,59.02,57.47,55.18,52.80,51.01.
ESI-HRMS m/z calcd for C13H22N3O2 +252.1707,found 252.1705[M+H]+.
to a solution of compound 6a (1g,2.8mmol,1equiv) in DMF (50mL) was added compound 12(1.1g,4.2mmol,1.5equiv), and p-toluenesulfonic acid (0.6g,3.4mmol,1.2equiv), and the mixture was heated to 110 ℃ and stirred for 5 h. After completion of the reaction, the reaction mixture was poured into 200mL of water, followed by extraction with ethyl acetate (50mL × 3 times). The ethyl acetate layers were combined, dried over anhydrous sodium sulfate, filtered, and the concentrated filtrate was rotary-evaporated, and separated by silica gel column chromatography (dichloromethane/methanol ═ 20/1 to 5/1) to give compound 27aa (0.72g, yellow solid, yield 46.2%); compound 27aa was structurally characterized as follows:
1H NMR(400MHz,CDCl3,δppm):8.80(dd,J=1.2Hz,9.4Hz,1H),8.33(s,1H),8.18(dd,J=1.4Hz,4.4Hz,1H),8.07(s,1H),7.92(d,J=8.6Hz,1H),7.29-7.26(m,2H),6.52(d,J=2.2Hz,1H),6.46(dd,J=2.2Hz,8.7Hz,1H),3.84(s,3H),3.71(t,J=5.2Hz,2H),3.28(s,3H),3.19(t,J=4.5Hz,4H),3.04(s,3H),2.76(t,J=4.7Hz,4H),2.67(t,J=5.3Hz,2H),
13C NMR(400MHz,CDCl3,δppm):157.58,155.00,154.51,149.49,147.20,143.99,142.39,133.06,130.77,123.63,121.63,120.90,107.59,105.30,100.27,59.09,57.40,55.31,52.64,49.63,37.39,34.90.
ESI-HRMS m/z calcd for C24H32ClN8O4S+563.1950,found 563.1941[M+H]+.
EXAMPLE 2 organic Synthesis of Compound 27ab
1H NMR(400MHz,CDCl3,δppm):8.80(d,J=6.3Hz,1H),8.35(s,1H),8.19-8.17(m,2H),7.94(d,J=5.8Hz,1H),7.29-7.27(m,1H),7.19(s,1H),6.53(d,J=1.6Hz,1H),6.47(dd,J=1.6Hz,5.8Hz,1H),3.85(s,3H),3.69(t,J=3.4Hz,2H),3.29(s,3H),3.20(t,J=3.1Hz,4H),3.05(s,3H),2.75(t,J=2.8Hz,4H),2.66(t,J=3.4Hz,2H).
13C NMR(400MHz,CDCl3,δppm):158.66,157.92,156.26,150.01,147.67,144.65,142.91,133.84,131.36,124.15,122.34,121.42,108.35,100.95,94.85,59.72,57.82,55.91,55.84,53.22,50.22,37.88,35.55.
ESI-HRMS m/z calcd for C24H32BrN8O4S+607.1445,found 607.1446[M+H]+.
EXAMPLE 3 organic Synthesis of Compound 27ac
1H NMR(400MHz,CDCl3,δppm):8.85(d,J=8.2Hz,1H),8.19(dd,J=1.2Hz,4.4Hz,1H),8.00-7.96(m,3H),7.32-7.29(m,1H),7.19(s,1H),6.54(d,J=2.2Hz,1H),6.50(dd,J=2.0Hz,8.7Hz,1H),3.86(s,3H),3.75(t,J=4.8Hz,2H),3.28(s,3H),3.23(s,4H),3.04(s,3H),2.82(s,4H),2.72(s,2H).
13C NMR(400MHz,CDCl3,δppm):155.35,149.20,146.75,143.76,142.29,142.00,141.16,140.97,132.96,130.34,123.76,122.44,120.18,107.92,100.54,59.25,57.26,55.36,52.73,49.71,37.56,34.86.
ESI-HRMS m/z calcd for C24H32FN8O4S+547.2246,found 547.2248[M+H]+.
EXAMPLE 4 organic Synthesis of Compound 27ae
1H NMR(400MHz,CDCl3,δppm):8.99(dd,J=1.4Hz,8.3Hz,1H),8.28(s,1H),8.14(dd,J=1.5Hz,4.5Hz,1H),8.09(d,J=8.6Hz,1H),7.76(s,1H),7.31-7.28(m,1H),7.11(s,1H),6.55-6.50(m,2H),3.91(s,3H),3.87(s,3H),3.75(t,J=5.0Hz,2H),3.28(s,3H),3.25-3.22(m,4H),3.07(s,3H),2.85-2.83(m,4H),2.74(t,J=5.1Hz,2H).
13C NMR(400MHz,CDCl3,δppm):153.78,151.34,148.99,146.16,143.42,141.51 136.5,135.05,133.68,129.65 123.91,123.41,119.75,108.28,100.84,59.35,57.24,57.17,57.17,55.43,52.82,49.88,37.54,35.12.
ESI-HRMS m/z calcd for C25H34N8O5S+559.2446,found 559.2443[M+H]+.
EXAMPLE 5 organic Synthesis of Compound 28ab
To a solution of 4-fluoro-2-methoxynitrobenzene (compound 9) (10g,58.4mmol,1equiv) in 1, 4-dioxane (300mL) was added piperazine (compound 13) (6.0g,70.0mmol,1.2equiv), the temperature was raised to 120 ℃ and the mixture was stirred for 2 h. The reaction was concentrated by rotary evaporation and chromatographed on silica gel (dichloromethane/methanol 20/1 to 5/1) to give compound 14(12.1g, yellow solid, 87.6% yield); compound 14 was structurally characterized as follows:
1H NMR(400MHz,DMSO-d6,δppm):7.90(d,J=8.9Hz,1H),6.64-6.61(m,2H),6.28(d,J=2.0Hz,1H),3.90(s,3H),3.65(t,J=4.8Hz,4H),3.22(t,J=5.0Hz,4H).
13C NMR(400MHz,DMSO-d6,δppm):155.84,154.80,129.42,128.21,105.96,98.36,56.65,44.01,42.50.
ESI-HRMS m/z calcd for C11H16N3O3 +238.1186,found 238.1192[M+H]+.
to a solution of compound 14(10g,42.2mmol,1equiv) in acetonitrile (200mL) was added 1-bromo-2-fluoroethane (7.9g,63.2mmol,1.5equiv) and triethylamine (6.4g,63.3mmol,1.5equiv) at room temperature, and stirring was continued until the starting material was completely dissolved, and the temperature was raised to 90 ℃ and stirred for 3 hours. After completion of the reaction, the reaction mixture was poured into 500mL of water, followed by extraction with ethyl acetate (300mL × 3 times). The ethyl acetate layers were combined, dried over anhydrous sodium sulfate, filtered, and the concentrated filtrate was rotary-evaporated, and separated by silica gel column chromatography (dichloromethane/methanol ═ 20/1 to 5/1) to give compound 15(11.0g, yellow solid, yield 92.1%); compound 15 is structurally characterized as follows:
1H NMR(400MHz,DMSO-d6,δppm):7.89(d,J=9.4Hz,1H),6.61(dd,J=2.2Hz,9.4Hz,1H),6.53(d,J=1.8Hz,1H),4.66(t,J=4.4Hz,1H),4.54(t,J=4.4Hz,1H),3.91(s,3H),3.45(s,4H),2.73-2.59(m,6H).
13C NMR(400MHz,DMSO-d6,δppm):156.14,155.58,128.32,105.46,97.19,82.77,81.13,57.58,57.38,56.45,52.63,46.52.
ESI-HRMS m/z calcd for C13H19FN3O3 +284.1405,found 284.1412[M+H]+.
a solution of compound 15(10g,35.3mmol,1equiv) in methanol (200mL) was added to the autoclave at room temperature, 10% palladium on carbon (1g,0.1equiv) was added, hydrogen was introduced to 10bar, and the reaction was carried out at room temperature for 2 hours. Palladium on carbon was filtered through celite, and the filtrate was concentrated by rotary evaporation to give compound 16(8.8g, a violet black solid, yield 99.0%); compound 16 was structurally characterized as follows:
1H NMR(400MHz,CDCl3,δppm):6.63(d,J=8.3Hz,1H),6.51(d,J=2.4Hz,1H),6.41(dd,J=2.2Hz,8.3Hz,1H),4.66(t,J=4.8Hz,1H),4.55(t,J=4.8Hz,1H),3.81(s,3H),3.09(t,J=4.9Hz,4H),2.79-2.68(m,6H).
13C NMR(400MHz,CDCl3,δppm):147.67,144.56,129.90,115.12,109.12,102.01,82.43,80.77,57.95,57.75,55.10,53.37,50.80.
ESI-MS m/z calcd for C13H21FN3O+254.16,found 254.38[M+H]+.
to compound 6a prepared by the method described in example 1, compound 16(1.1g,4.2mmol,1.5equiv), and p-toluenesulfonic acid (0.6g,3.4mmol,1.2equiv) were added to a solution of compound 6a (1g,2.8mmol,1equiv) in DMF (50mL), and the mixture was stirred at 110 ℃ for 5 hours. After completion of the reaction, the reaction mixture was poured into 200mL of water, followed by extraction with ethyl acetate (50mL × 3 times). The ethyl acetate layers were combined, dried over anhydrous sodium sulfate, filtered, and the concentrated filtrate was rotary-evaporated, and separated by silica gel column chromatography (dichloromethane/methanol ═ 20/1 to 5/1) to give compound 28ab (1.1g, yellow solid, yield 71.1%). Compound 28ab structure was characterized as follows:
1H NMR(400MHz,CDCl3,δppm):8.82(dd,J=1.3Hz,8.2Hz,1H),8.35(s,1H),8.20(dd,J=1.5Hz,4.5Hz,1H),8.10(s,1H),7.95(d,J=8.7Hz,1H),7.30-7.27(m,1H),7.20(s,1H),6.55(d,J=2.3Hz,1H),6.50-6.47(m,1H),4.71(t,J=4.6Hz,1H),4.59(t,J=4.6Hz,1H),3.86(s,3H),3.30(s,3H),3.22(t,J=4.6Hz,4H),3.06(s,3H),2.76-2.71(m,6H).
13C NMR(400MHz,CDCl3,δppm):157.69,155.10,154.62,149.58,147.46,144.09,142.39,133.19,130.87,123.61,121.65,121.02,107.64,100.37,99.71,82.51,82.47,57.99,57.80,55.36,53.27,49.81,37.43,34.99.
ESI-HRMS m/z calcd for C24H31ClFN8O3S+565.1907,found 565.1911[M+H]+.
EXAMPLE 6 organic Synthesis of Compound 28bb
Compound 6b was prepared according to the procedure of example 2 and compound 16 was prepared according to the procedure of example 5, except that compound 6b was used instead of compound 6a to react with compound 16, to give compound 28bb (1.0g, yellow-green solid, 63.5% yield) structurally close to compound 28ab, which was characterized as follows:
1H NMR(400MHz,CDCl3,δppm):8.79(dd,J=1.1Hz,8.2Hz,1H),8.37(s,1H),8.19-8.18(m,2H),7.90(s,1H),7.28-7.26(m,2H),6.54(d,J=2.3Hz,1H),6.48(dd,J=2.3Hz,8.7Hz,1H),4.73(t,J=4.6Hz,1H),4.61(t,J=4.6Hz,1H),3.85(s,3H),3.29(s,3H),3.24(t,J=4.5Hz,4H),3.06(s,3H),2.81-2.78(m,6H).
13C NMR(400MHz,CDCl3,δppm):158.19,157.27,155.78,149.76,147.38,144.11,142.44,133.29,130.85,123.67,121.64,121.29,107.76,100.45,94.26,82.19,80.52,57.91,57.71,55.39,53.20,49.60,37.38,35.06.
ESI-MS m/z calcd for C24H31BrFN8O3S+609.14,found 609.17[M+H]+.
example 7 organic Synthesis of Compound 31bb
3,4, 5-Trimethoxybenzoic acid (Compound 18) (20.00g,94.3mmol,1equiv) was added to a mixture of nitric acid (100mL) and acetic acid (200mL) at 0 ℃. The temperature is increased to 40 ℃, and the mixture is stirred for 4 hours. The reaction solution was poured into ice water (500mL), a white solid precipitated, and the solid was collected by filtration to give compound 19(13.6g, yield 68.1%, dark red solid); compound 19 was structurally characterized as follows:
1H NMR(400MHz,CDCl3,δppm):7.52(s,2H),3.948(s,3H),3.944(s,6H).
13C NMR(400MHz,CDCl3,δppm):152.60,143.50,143.15,101.07,60.86,56.21.
to a solution of compound 19(10.00g,46.9mmol,1equiv) in anhydrous dichloromethane (200mL) was added dropwise boron trichloride (1.0mol/L dichloromethane solution) (93.8mL,93.8mmol,2.0equiv) at 0 ℃. Slowly heating to 40 ℃, and stirring for 5 h. After completion of the reaction, the reaction mixture was poured into 500mL of water, followed by extraction with ethyl acetate (300mL × 3 times). The ethyl acetate layers were combined, dried over anhydrous sodium sulfate, filtered, and the concentrated filtrate was rotary-evaporated, and subjected to silica gel column chromatography (dichloromethane/methanol ═ 20/1 to 10/1) to give compound 20(3.0g, yellow solid)Bulk, yield 32.8%); compound 20 is structurally characterized as follows:1H NMR(400MHz,CDCl3,δppm):7.53(s,2H),3.95(s,6H).
to a solution of compound 20(2g,10.0mmol,1equiv) in acetonitrile (50mL) was added 1-bromo-2-fluoroethane (1.9g,15.0mmol,1.5equiv), and triethylamine (1.5g,15.0mmol,1.5equiv) at room temperature, and the mixture was heated to 80 ℃ and stirred for 2 h. After completion of the reaction, the reaction mixture was poured into 500mL of water, followed by extraction with ethyl acetate (200mL × 3 times). The ethyl acetate layers were combined, dried over anhydrous sodium sulfate, filtered, and the concentrated filtrate was rotary-evaporated, and separated by silica gel column chromatography (dichloromethane/methanol ═ 20/1 to 10/1) to give compound 25(2.2g, yellow solid, yield 90.0%); compound 25 is structurally characterized as follows:
1H NMR(400MHz,CDCl3,δppm):7.52(s,2H),4.77(t,J=4.0Hz,1H),4.21(t,J=4.0Hz,1H),4.38(t,J=4.2Hz,1H),4.31(t,J=4.1Hz,1H),3.93(s,6H).
13C NMR(400MHz,CDCl3,δppm):152.72,143.50,142.05,101.01,83.26,81.57,72.03,71.83,56.26
a solution of compound 25(2g,8.1mmol,1equiv) in methanol (50mL) was added to the autoclave at room temperature, 10% palladium on carbon (0.2g,0.1equiv) was added, hydrogen was introduced to 10bar, and the reaction was carried out at room temperature for 2 hours. Palladium on carbon was filtered through celite, and the filtrate was concentrated by rotary evaporation to give compound 26(1.6g, a violet black solid, 92.0% yield); compound 26 is structurally characterized as follows:
1H NMR(400MHz,CDCl3,δppm):5.93(s,2H),4.73(t,J=4.2Hz,1H),4.61(t,J=4.2Hz,1H),4.18(t,J=4.2Hz,1H),4.11(t,J=4.4Hz,1H),3.80(s,6H).
13C NMR(400MHz,CDCl3,δppm):153.71,142.88,129.04,92.51,83.36,71.95,71.75,55.73.
ESI-HRMS m/z calcd for C10H15FNO3 +216.1030,found 216.1034[M+H]+.
referring to preparation of compound 6b by the method of example 2, compound 26(0.9g,4.2mmol,1.5equiv), and p-toluenesulfonic acid (0.6g,3.4mmol,1.2equiv) were added to a solution of compound 6b (1g,2.8mmol,1equiv) in DMF (50mL), and the mixture was stirred at 110 ℃ for 5 h. After completion of the reaction, the reaction mixture was poured into 200mL of water, followed by extraction with ethyl acetate (50mL × 3 times). The ethyl acetate layers were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated by rotary evaporation, and separated by silica gel column chromatography (dichloromethane/methanol ═ 20/1 to 5/1) to give compound 31bb (1.3g, tan solid, yield 88.3%); compound 31bb was structurally characterized as follows:
1H NMR(400MHz,CDCl3,δppm):8.80(d,J=7.9Hz,1H),8.42(s,1H),8.16(d,J=3.4Hz,1H),8.11(s,1H),7.31(s,1H),7.26-7.22(m,1H),6.74(s,2H),4.76(t,J=4.0Hz,1H),4.65(t,J=4.0Hz,1H),4.26(t,J=4.1Hz,1H),4.19(t,J=4.1Hz,1H),3.75(s,6H),3.28(s,3H),3.06(s,3H).
13C NMR(400MHz,CDCl3,δppm):157.57,155.12,154.31,153.11,143.94,142.50,135.17,133.02,132.49,130.17,123.86,106.17,98.63,83.39,81.71,71.92,71.72,55.92,37.49,34.93.
ESI-HRMS m/z calcd for C21H25ClFN6O5S+527.1274,found 527.1270[M+H]+.
example 8 Synthesis of Compound 31ab
Compound 6a was obtained according to the procedure of example 1, and compound 6a was reacted with compound 26 instead of compound 6b according to the procedure of example 7 to give compound 31ab (1.3g, tan solid, yield 88.3%); the structure of compound 31ab is characterized as follows:
1H NMR(400MHz,CDCl3,δppm):8.80(d,J=7.9Hz,1H),8.42(s,1H),8.16(d,J=3.4Hz,1H),8.11(s,1H),7.31(s,1H),7.26-7.22(m,1H),6.74(s,2H),4.76(t,J=4.0Hz,1H),4.65(t,J=4.0Hz,1H),4.26(t,J=4.1Hz,1H),4.19(t,J=4.1Hz,1H),3.75(s,6H),3.28(s,3H),3.06(s,3H).
13C NMR(400MHz,CDCl3,δppm):157.57,155.12,154.31,153.11,143.94,142.50,135.17,133.02,132.49,130.17,123.86,106.17,98.63,83.39,81.71,71.92,71.72,55.92,37.49,34.93.
ESI-HRMS m/z calcd for C21H25ClFN6O5S+527.1274,found 527.1270[M+H]+.
EXAMPLE 9 Synthesis of Compound 31bc
Compound 6c was obtained according to the procedure of example 3, and compound 31bc (0.4g, tan solid, 28.0% yield) structurally close to compound 31bb was obtained by reacting compound 26 with compound 6c instead of compound 6b according to the procedure of example 7, and its structure was characterized as follows:
1H NMR(400MHz,CDCl3,δppm):8.82(d,J=8.1Hz,1H),8.18(d,J=3.3Hz,1H),8.07(s,1H),8.01(d,J=1.6Hz,1H),7.30-7.27(m,1H),7.06(s,1H),6.76(s,2H),4.77(t,J=4.0Hz,1H),4.65(t,J=4.0Hz,1H),4.26(t,J=4.2Hz,1H),4.19(t,J=4.1Hz,1H),3.78(s,6H),3.29(s,3H),3.05(s,3H).
13C NMR(400MHz,CDCl3,δppm):153.50,149.85,149.75,144.16,142.90,135.79,133.12,132.65,130.28,124.26,98.49,83.75,82.06,72.28,72.08,56.30,37.98,35.19.
ESI-HRMS m/z calcd for C21H25F2N6O5S+511.1570,found 511.1578[M+H]+.
EXAMPLE 10 Synthesis of Compound 31be
Compound 6e was prepared according to the procedure of example 4; referring to the procedure of example 7, compound 6e instead of compound 6b was reacted with compound 26 to give compound 31be (0.7g, tan solid, 50.0% yield) structurally close to compound 31bb, which was characterized as follows:
1H NMR(400MHz,CDCl3,δppm):8.97(d,J=8.2Hz,1H),8.38(s,1H),8.12(d,J=3.6Hz,1H),7.71(s,1H),7.38(s,1H),7.27-7.24(m,1H),6.79(s,2H),4.76(t,J=4.0Hz,1H),4.64(t,J=4.0Hz,1H),4.25(t,J=4.2Hz,1H),4.18(t,J=4.2Hz,1H),3.92(s,3H),3.78(s,6H),3.28(s,3H),3.07(s,3H).
13C NMR(400MHz,CDCl3,δppm):153.71,153.46,151.82,143.77,142.08,136.57,135.58,135.32,133.76,132.07,129.60,124.36,97.98,83.75,82.06,72.28,72.08,57.38,56.28,37.90,35.38.
ESI-HRMS m/z calcd for C22H28FN6O6S+523.1770,found 523.1777[M+H]+.
EXAMPLE 11 Synthesis of Compound 31bd
Preparing a compound 4 according to the method of example 1, and reacting the compound 4 with 5-methyl-2, 4-dichloropyrimidine instead of 2,4, 5-trichloropyrimidine to obtain a compound 6d which has a structure similar to that of the compound 6 a; referring to the procedure of example 7, compound 6d was reacted with compound 26 instead of compound 6b to give compound 31bd (0.4g, tan solid, yield 28.0%) having a structure close to that of compound 31 bb. The structure is characterized as follows:
1H NMR(400MHz,CDCl3,δppm):8.87(dd,J=0.9Hz,8.3Hz,1H),8.13(dd,J=1.3Hz,4.4Hz,1H),7.96(s,1H),7.80(s,1H),7.28-7.22(m,2H),6.78(s,2H),4.76(t,J=4.0Hz,1H),4.64(t,J=4.0Hz,1H),4.25(t,J=4.2Hz,1H),4.17(t,J=4.2Hz,1H),3.74(s,6H),3.28(s,3H),3.04(s,3H),2.17(s,3H).
13C NMR(400MHz,CDCl3,δppm):158.35,158.13,155.67,153.06,143.45,141.82,135.97,133.76,131.87,130.23,123.89,106.74,98.04,83.38,81.69,71.91,71.71,55.86,37.3,34.71,12.76.
ESI-HRMS m/z calcd for C22H28FN6O5S+507.1820,found 507.1817[M+H]+.
EXAMPLE 12 Synthesis of Compound 43
To a solution of 2-amino-N-methylbenzamide (Compound 7) (10g,66.6mmol,1equiv) in DMF (200mL) was added 5-bromo-2, 4-dichloropyrimidine (Compound 5b) (14.5g,79.7mmol,1.2equiv), K2CO3(13.8g,100.0mmol,1.5equiv), the mixture was stirred at 90 ℃ for 5 h. A yellow solid precipitated from the reaction solution, and the reaction solution was poured into a mixed solution of acetonitrile/water (v: v ═ 1:1,500mL), stirred, filtered, and the filter cake was washed with acetonitrile, and the filter cake was collected as the product compound 8b (15.9g, yellow solid, yield 80.7%); the structure is characterized as follows:
1H NMR(400MHz,DMSO-d6,δppm):12.16(s,1H),8.83(s,1H),8.51(d,J=8.3Hz,1H),8.45(s,1H),7.79(d,J=7.8Hz,1H),7.60(t,J=7.7Hz,1H),7.22(t,J=7.5Hz,1H),2.80(d,J=4.4Hz,3H).
13C NMR(400MHz,DMSO-d6,δppm):169.17,157.15,156.68,155.83,138.79,132.29,128.60,123.62,121.69,121.36,115.37,26.80.
ESI-HRMS m/z calcd for C12H11Cl2N4O+297.0304,found 297.0310[M+H]+.
to a solution of p-aminophenethyl alcohol (compound 38) (5.0g,36.5mmol,1equiv) in DMF (200mL) were added compound 8b (10.0g,29.5mmol,0.8equiv) and p-toluenesulfonic acid (2.0g,11.6mmol,0.3equiv), and the reaction was stirred at 100 ℃ for 5 h. After completion of the reaction, the reaction mixture was poured into 200mL of water, followed by extraction with ethyl acetate (50mL × 3 times). The ethyl acetate layers were combined, dried over anhydrous sodium sulfate, filtered, and the concentrated filtrate was rotary-evaporated, and separated by silica gel column chromatography (dichloromethane/methanol ═ 20/1 to 5/1) to give compound 39(9.3g, white solid, yield 57.7%); the structure is characterized as follows:
1H NMR(400MHz,DMSO-d6,δppm):11.30(s,1H),9.32(s,1H),8.70(d,J=4.5Hz,1H),8.63(d,J=8.6Hz,1H),8.22(s,1H),7.70(d,J=7.8Hz,1H),7.51(d,J=8.4Hz,2H),7.46(m,1H),7.12(m,1H),7.07(d,J=8.4Hz,2H),4.58(t,J=5.2Hz,1H),3.55(dd,J=7.2Hz,12.3Hz,2H),2.77(d,J=4.5Hz,3H),2.64(t,J=7.1Hz,2H).
13C NMR(400MHz,DMSO-d6,δppm):169.34,158.76,158.04,156.32,139.75,138.56,133.42,131.80,129.27,128.45,122.52,122.28,121.70,120.30,94.52,62.96,26.84.
ESI-HRMS m/z calcd for C20H21BrN5O2 +442.0873,found 442.0869[M+H]+.
to a solution of compound 39(1g,2.2mmol,1equiv) in dichloromethane (50mL) at 0 ℃ was added triethylamine (10g,4.9mmol,2.2equiv), and the mixture was stirred at 0 ℃ for 10 minutes, and a solution of p-toluenesulfonyl chloride (1.0g,5.2mmol,2.3equiv) in dichloromethane (5mL) was slowly added dropwise, and after the addition was completed, the mixture was warmed to room temperature and stirred for 2 hours. The reaction solution was concentrated by rotary evaporation and subjected to silica gel column chromatography (dichloromethane/methanol: 20/1 to 10/1) to obtain compound 40(1.1g, yellow solid, yield 84.6%). The structure is characterized as follows:
1H NMR(400MHz,DMSO-d6,δppm):11.34(s,1H),9.39(s,1H),8.70(d,J=2.9Hz,1H),8.61(d,J=3.3Hz,1H),8.24(s,1H),7.70(d,J=5.2Hz,1H),7.64(d,J=5.5Hz,2H),7.49(d,J=5.4Hz,2H),7.44(t,J=5.0Hz,1H),7.36(d,J=5.4Hz,2H),7.11(t,J=5.0Hz,1H),7.00(d,J=5.5Hz,2H),4.17(t,J=4.3Hz,2H),2.80(m,5H),2.33(s,3H).
13C NMR(400MHz,DMSO-d6,δppm):169.06,157.23,145.91,138.37,136.19,131.90,130.64,129.70,128.65,128.52,127.99,126.03,124.12,122.87,122.55,94.45,62.77,38.99,26.88,21.31.
ESI-HRMS m/z calcd for C27H27BrN5O4S+596.0962 found to be free of [ M + H [ ]]+.
A solution of compound 40(0.5g,0.8mmol,1equiv) in tetrahydrofuran (50mL) and a solution of tetrabutylammonium fluoride in 1M tetrahydrofuran (4.0mL,4.0mmol,5equiv) were added to the digestion tank, and the reaction was stirred at 85 ℃ for 1h after the tank was closed. After completion of the reaction, the reaction mixture was poured into 200mL of water, followed by extraction with ethyl acetate (50mL × 3 times). The ethyl acetate layers were combined, dried over anhydrous sodium sulfate, filtered, and the concentrated filtrate was rotary-evaporated, and separated by silica gel column chromatography (dichloromethane/methanol ═ 20/1 to 5/1) to give compound 43(0.3g, yellow-green solid, yield 85.4%); the structure is characterized as follows:
1H NMR(400MHz,DMSO-d6,δppm):11.32(s,1H),9.37(s,1H),8.70(d,J=2.8Hz,1H),8.62(d,J=4.5Hz,1H),8.23(s,1H),7.70(d,J=4.8Hz,1H),7.55(d,J=5.5Hz,2H),7.45(t,J=5.1Hz,1H),7.12(m,3H),4.62(t,J=4.3Hz,1H),4.54(t,J=4.3Hz,1H),2.91(t,J=4.3Hz,1H),2.87(t,J=4.3Hz,1H),2.77(d,J=3.0Hz,2H).
13C NMR(400MHz,DMSO-d6,δppm):169.33,158.70,158.05,156.32,139.71,139.10,131.80,130.18,129.41,128.46,122.57,122.28,121.71,120.34,94.67,85.43,83.78,36.15,35.95,26.84.
ESI-HRMS m/z calcd for C20H20BrFN5O+444.0830,found 444.0834[M+H]+.
EXAMPLE 13 Synthesis of Compound 44
To a solution of 2, 4-dichloro-5-trifluoromethylpyrimidine (compound 35) (1g,4.6mmol,1equiv) in THF (50mL) at 0 deg.C was added 3-aminomethylbenzenesulfonyl hydrochloride (compound 36) (1.1g,5.9mmol,1.3equiv), diisopropylethylamine (1.8g,13.8mmol,3equiv), and the suspension was stirred at 0 deg.C overnight. The reaction was concentrated by rotary evaporation, the residue was dissolved in dichloromethane (100mL) and filtered with stirring, the filter cake was washed with dichloromethane (100mL), water (100mL) and the filter cake was collected as product 37(0.6g, white solid, 37.5% yield);
1H NMR(400MHz,DMSO-d6,δppm):8.60(t,J=3.8Hz,1H),8.41(s,1H),7.87(s,1H),7.79(d,J=4.9Hz,1H),7.62(m,2H),4.68(d,J=3.9Hz,2H),3.15(s,3H).
13C NMR(400MHz,DMSO-d6,δppm):168.09,163.86,161.34,146.40,145.40,137.94,135.08,131.36,131.18,110.93,110.61,49.17,49.04.
ESI-HRMS m/z calcd for C13H12ClF3N3O2S+366.0285,found 366.0281[M+H]+.
to a solution of p-aminophenethyl alcohol (compound 38) (5.0g,36.5mmol,1equiv) in DMF (200mL) were added compound 37(10.0g,27.3mmol,0.7equiv) and p-toluenesulfonic acid (2.0g,11.6mmol,0.3equiv), and the reaction was stirred at 100 ℃ for 5 h. After completion of the reaction, the reaction mixture was poured into 200mL of water, followed by extraction with ethyl acetate (50mL × 3 times). The ethyl acetate layers were combined, dried over anhydrous sodium sulfate, filtered, and the concentrated filtrate was rotary-evaporated, and separated by silica gel column chromatography (dichloromethane/methanol ═ 20/1 to 5/1) to give compound 41(7.4g, white solid, yield 43.6%); the structure is characterized as follows:
1H NMR(400MHz,CD3OD,δppm):8.10(s,1H),7.78(d,J=5.3Hz,2H),7.49(m,2H),7.19(s,2H),7.11(s,2H),4.48(s,2H),3.73(t,J=4.6Hz,2H),3.00(s,3H),2.79(t,J=4.6Hz,2H).
ESI-HRMS m/z calcd for C21H22F3N4O3S+467.1359,found 467.1365[M+H]+.
to a solution of compound 41(1g,2.1mmol,1equiv) in dichloromethane (50mL) at 0 ℃ was added triethylamine (0.5g,4.9mmol,2.3equiv), and the mixture was stirred at 0 ℃ for 10 minutes, and a solution of p-toluenesulfonyl chloride (1.0g,5.2mmol,2.4equiv) in dichloromethane (5mL) was slowly added dropwise, and after completion of the addition, the mixture was warmed to room temperature and stirred for 2 hours. The reaction solution was concentrated by rotary evaporation and subjected to silica gel column chromatography (dichloromethane/methanol: 20/1 to 10/1) to obtain compound 42(1.0g, white solid, yield 77.8%). The structure is characterized as follows:
1H NMR(400MHz,DMSO-d6,δppm):9.54(s,1H),8.21(s,1H),7.88(s,2H),7.77(d,J=4.8Hz,1H),7.66(d,J=7.2Hz,2H),7.59(s,2H),7.46(d,J=6.8Hz,1H),7.38(d,J=6.0Hz,2H),7.09(d,J=6.2Hz,1H),6.97(d,J=7.2Hz,1H),4.72(s,2H),4.19(t,J=6.5Hz,2H),3.08(s,3H),2.80(t,J=7.6Hz,2H),2.35(s,3H).
13C NMR(400MHz,DMSO-d6,δppm):158.20,146.04,141.43,140.79,138.27,136.19,135.69,132.46,130.05,129.59,128.62,126.10,126.02,125.72,125.68,121.50,119.25,62.66,44.36,43.98,38.94,21.31.
ESI-HRMS m/z calcd for C28H28F3N4O5S2 +621.1448,found 621.1451[M+H]+.
a solution of compound 42(0.5g,0.8mmol,1equiv) in tetrahydrofuran (50mL) and a solution of tetrabutylammonium fluoride in 1M tetrahydrofuran (4.0mL,4.0mmol,5equiv) were added to the digestion tank, and the reaction was stirred at 85 ℃ for 1h after the tank was closed. After completion of the reaction, the reaction mixture was poured into 200mL of water, followed by extraction with ethyl acetate (50mL × 3 times). The ethyl acetate layers were combined, dried over anhydrous sodium sulfate, filtered, and the concentrated filtrate was rotary-evaporated, and separated by silica gel column chromatography (dichloromethane/methanol ═ 20/1 to 5/1) to give compound 44(0.3g, white solid, yield 81.5%); the structure is characterized as follows:
1H NMR(400MHz,CDCl3,δppm):8.17(s,1H),7.91(s,1H),7.85(d,J=5.0Hz,1H),7.57(m,2H),7.38(d,J=5.2Hz,2H),7.15(d,J=5.4Hz,2H),4.82(d,J=3.8Hz,2H),4.65(t,J=4.0Hz,1H),4.58(d,J=4.0Hz,1H),2.99(m,5H).
13C NMR(400MHz,CDCl3,δppm):59.13,158.76,144.23,141.10,139.80,136.59,133.03,132.98,132.39,129.97,129.50,126.57,126.38,120.78,84.95,83.27,59.32,44.44,36.46,36.26.
ESI-MS m/z calcd for C21H21F4N4O2S+469.13,found 469.33[M+H]+.
example 14 Synthesis of Label precursor Compound 29, Compound 32, Compound 33
Referring to example 3, compound 14 was prepared, and a solution of compound 14(10g,42.1mmol,1equiv) in methanol (200mL) was added to an autoclave at room temperature, 10% palladium on carbon (1g,0.1equiv) was added, hydrogen was introduced to 10bar, and the reaction was carried out at room temperature for 2 hours. Palladium on carbon was filtered through celite, and the filtrate was concentrated by rotary evaporation to give compound 17(8.6g, a violet black solid, yield 99.0%); compound 23 is structurally characterized as follows:
1H NMR(400MHz,CDCl3,δppm):6.61(d,J=7.8Hz,1H),6.43(s,1H),6.35(s,1H),3.78(s,3H),3.27(s,4H),3.19(s,4H).
13C NMR(400MHz,CDCl3,δppm):147.65,143.13,131.07,115.00,110.24,102.78,55.09,48.35,43.35.
ESI-HRMS m/z calcd for C11H18N3O+208.1444,found 208.1451[M+H]+.
compound 6a was prepared by the method described in example 1, and to a solution of Compound 6a (1g,2.8mmol,1equiv) in DMF (50mL) were added compound 23(0.9g,4.2mmol,1.5equiv), and p-toluenesulfonic acid (0.6g,3.4mmol,1.2equiv), and the mixture was heated to 110 ℃ and stirred for 5 h. After completion of the reaction, the reaction mixture was poured into 200mL of water, followed by extraction with ethyl acetate (50mL × 3 times). The ethyl acetate layers were combined, dried over anhydrous sodium sulfate, filtered, and the concentrated filtrate was rotary-evaporated, and separated by silica gel column chromatography (dichloromethane/methanol ═ 20/1 to 5/1) to give compound 29(1.3g, pale yellow solid, yield 90.5%). Compound 29 is structurally characterized as follows:
1H NMR(400MHz,CDCl3,δppm):8.79(d,7.8Hz,1H),8.37(s,1H),8.22(d,J=3.6Hz,1H),8.11(s,1H),8.04(d,J=8.7Hz,1H),7.77(d,J=7.7Hz,1H),7.31-7.29(m,1H),7.22(d,J=6.7Hz,1H),6.51(s,1H),6.47(d,J=8.8Hz,1H),3.86(s,3H),3.40-3.39(m,8H),3.30(s,3H),3.05(s,3H).
13C NMR(400MHz,CDCl3,δppm):157.38,155.15,154.54,149.17,145.86,144.27,142.64,133.06,130.95,125.47,123.61,120.24,109.05,105.77,101.44,55.47,47.90,43.60,37.39,34.94.
ESI-HRMS m/z calcd for C22H28ClN8O3S+519.1688,found 519.1683[M+H]+.
ESI-MS m/z calcd for C8H12NO3 +170.08,found 170.08[M+H]+.
compound 6b was prepared according to the method of example 2, and to a solution of Compound 6b (1g,2.5mmol,1equiv) in DMF (50mL) were added compound 31(0.6g,3.8mmol,1.5equiv), and p-toluenesulfonic acid (0.5g,3.0mmol,1.2equiv), and the mixture was heated to 110 ℃ and stirred for 5 h. After completion of the reaction, the reaction mixture was poured into 200mL of water, followed by extraction with ethyl acetate (50mL × 3 times). The ethyl acetate layers were combined, dried over anhydrous sodium sulfate, filtered, and the concentrated filtrate was rotary-evaporated, and separated by silica gel column chromatography (dichloromethane/methanol ═ 20/1 to 5/1) to give compound 32(0.42g, a reddish brown solid, yield 32.3%); compound 32 was structurally characterized as follows:
1H NMR(400MHz,CDCl3,δppm):8.72(s,1H),8.66(d,J=5.2Hz,1H),8.20(dd,J=1.0Hz,4.2Hz,1H),8.10(s,1H),7.22(dd,J=3.1Hz,5.5Hz,1H),6.68(s,2H),3.79(s,6H),3.29(s,3H),3.05(s,3H).
13C NMR(400MHz,CDCl3,δppm):157.07,156.62,147.07,144.64,143.64,132.89,132.41,130.84,129.99,129.76,124.19,100.93,94.50,56.50,37.79,35.28.
ESI-HRMS m/z calcd for C19H22BrN6O5S+525.0550,found 525.0541[M+H]+.
ESI-MS m/z calcd for C8H12NO3 +170.08,found 170.08[M+H]+.
referring to preparation of compound 6d in example 11, compound 30(0.7g,4.5mmol,1.5equiv), and p-toluenesulfonic acid (0.6g,3.6mmol,1.2equiv) were added to a solution of compound 6d (1g,3.0mmol,1equiv) in DMF (50mL), and the mixture was stirred at 110 ℃ for 5 h. After completion of the reaction, the reaction mixture was poured into 200mL of water, followed by extraction with ethyl acetate (50mL × 3 times). The ethyl acetate layers were combined, dried over anhydrous sodium sulfate, filtered, and the concentrated filtrate was rotary-evaporated, and separated by silica gel column chromatography (dichloromethane/methanol ═ 20/1 to 5/1) to give compound 33(0.59g, pale yellow solid, yield 42.7%); the structure is characterized as follows:
1H NMR(400MHz,CDCl3,δppm):8.86(d,J=5.5Hz,1H),8.11(d,J=3.0Hz,1H),7.93(s,1H),7.79(s,1H),7.23(dd,J=3.0Hz,5.4Hz,1H),6.96(s,1H),6.76(s,2H),3.80(s,6H),3.28(s,3H),3.04(s,3H),2.17(s,3H).
13C NMR(400MHz,CDCl3,δppm):158.89,158.75,155.92,147.05,143.67,142.03,134.21,131.83,131.12,130.44,124.23,106.72,99.62,77.42,77.30,77.10,76.78,56.39,37.99,35.10,13.08.
ESI-MS m/z calcd for C20H25N6O5S+461.16,found 461.19[M+H]+.
example 15 the Compound [ 2 ]18F]28ab、[18F]31bb and [ 2 ]18F]F-18 labeling and isolation purification of 31bd
15mg of Kryptofix 222 was dissolved in 0.7mL of anhydrous acetonitrile, 1mg of K2CO3Dissolving in 0.3mL water, and mixing to obtain 1.0mL Kryptofix 222/K2CO3An eluent; capturing on QMA column with the eluate18F-Leaching into a reaction flask, and adding N at 100 DEG C2Blowing the solvent in the reaction bottle to dry, then adding 0.5mL of anhydrous acetonitrile into the solvent, blowing the solvent to dry again, and repeating the process for three times to ensure that the water in the reaction bottle is fully removed; a solution of the labeled precursor 1, 2-bis-methylphenoxyethane (4mg) in anhydrous acetonitrile (0.3mL) was quickly added to the above reaction flask, sealed, and reacted at 110 ℃ for 10 min. After the reaction, the mixture was subjected to radio-HPLC separation and purification using acetonitrile/water at a ratio of 1:1 as the mobile phase at a flow rate of 4mL/min and a wavelength of 254nm on a C18 reversed-phase semi-preparative column (Agela Technologies, 5 μm,10X 250 mm). Product 2-, [ 2 ]18F]The retention time of fluoroethyl tosylate was 12 minutes.
2- [18F ] of the product of the previous step]HPLC receiver of fluoroethyl tosylate was collected in a 100mL sterile vial and 50mL water was added. The diluted product solution was loaded onto a Sep-Pak C-18 column, N2The Sep-Pak C-18 column was air dried, the product on the Sep-Pak C-18 column was eluted with 3mL of diethyl ether into a sterile vial and dried at 40 ℃ with nitrogen flow. A solution of the labeling precursor (compound 29, compound 32 or compound 33 prepared in example 6) in 4mg of acetonitrile (0.4mL) was added thereto, and anhydrous potassium carbonate (1mg) was further added thereto, followed by uniform mixing and reaction at 120 ℃ for 20 minutes. The column was purified by semi-preparative column (agela technologies, 5 μm,10X 250mm) to obtain a F-18 labeled radioactive compound [ alpha ], [ beta ] -n ] or a salt thereof18F]28ab、[18F]31bb and [ 2 ]18F]31bd。
As shown in FIG. 1, the product [ alpha ], [ product ]18F]The liquid phase retention time of 28ab is 10.7 minutes, and19F]the liquid phase co-injection analysis of 28ab confirmed the radioligand [ 2 ]18F]28ab accuracy.
As shown in FIG. 2, the product [ 2 ]18F]The liquid phase retention time of 31bb is 17.1 minutes and19F]the liquid phase coinjection analysis of 31bb confirmed the radioligand [ 2 ], [18F]Accuracy of 31 bb.
As shown in FIG. 3, the product [ 2 ]18F]31bd has a liquid phase retention time of 14.3 minutes and19F]the liquid phase coinjection analysis of 31bd confirmed the radioligand [ 2 ]18F]Accuracy of 31 bd.
Example 16 the Compound18F]43 and [ 2 ]18F]44F-18 labeling and isolation purification
15mg of Kryptofix 222 was dissolved in 0.7mL of anhydrous acetonitrile, 1mg of K2CO3Dissolving in 0.3mL water, and mixing to obtain 1.0mL Kryptofix 222/K2CO3An eluent; capturing on QMA column with the eluate18F-Leaching into a reaction flask, and adding N at 100 DEG C2Blowing the solvent in the reaction bottle to dry, then adding 0.5mL of anhydrous acetonitrile into the solvent, blowing the solvent to dry again, and repeating the process for three times to ensure that the water in the reaction bottle is fully removed; a solution (0.3mL) of the labeled precursor compound 40(2mg) prepared according to the method of example 12 (or the labeled precursor compound 42(2mg) prepared according to the method of example 13) in anhydrous acetonitrile was quickly added to the above reaction flask, sealed, and reacted at 120 ℃ for 20 min. After the reaction was completed, distilled water (10mL) was added to quench the reaction, and the reaction solution was drawn up with a syringe and passed through a Sep-Pak C18 solid phase extraction column, N, which was activated in advance2And (3) air-drying the Sep-Pak C18 solid-phase extraction column, then eluting the reaction product from the C18 small column by using 1mL of acetonitrile, and collecting eluent. The column was purified by semi-preparative column (Agela Technologies, 5 μm,10X 250mm) to obtain a F-18 labeled radioactive compound [ alpha ], [ beta ] -n ] or a salt thereof18F]43 or [ alpha ], [ beta ], [ alpha ], [ beta ]18F]44。
As shown in FIG. 4, the product [ 2 ]18F]43 has a liquid phase retention time of 9.2 minutes and is as defined in [1 ], [19F]43 liquid phase coinjection analysis confirmed the radioligand [ alpha ], [ beta ] -cyclodextrin18F]43 accuracy.
As shown in FIG. 5, the product [ 2 ]18F]44 has a liquid phase retention time of 8.3 minutes and is as defined in [ 2 ]19F]44 liquid phase coinjection analysis confirmed the radioligand [ alpha ], [ beta ] -cyclodextrin18F]44 accuracy.
Examples of the experiments
1. In-vitro FAK enzyme activity inhibition experiment and selective inhibition experiment of different kinase activities of standard compound
The 15 compounds prepared in the preceding examples were used as standards to be evaluated in this experiment.
We use(Homogeneous Time-Resolved Fluorescence ) kinEASETMTK kit and truncated human FAK (PTK2) [376 and 1052(end) amino acids of access number NP-722560.1]The enzyme was subjected to FAK enzyme activity inhibition experiments.
Optimization of enzyme concentration, enzyme reaction time and ATP concentration was first performed prior to the official test.
For the in vitro inhibition experiment of FAK enzyme activity, the optimized conditions are as follows: mu.L of kinase buffer solution of FAK (final concentration of the enzyme reaction step: 0.11 ng/. mu.L (10. mu.L)) in 2. mu.L of kinase buffer, 2. mu.L of saturated TK substrate-biotin solution (final concentration of the enzyme reaction step: 1. mu.M (10. mu.L)), and 2. mu.L of ATP in kinase buffer solution (final concentration of the enzyme reaction step: 13.8. mu.M (10. mu.L)) at room temperature for 50 minutes;
for selective inhibition experiments of different kinase activities, the optimized conditions were: mu.L of kinase buffer solution of kinase 2. mu.L (final concentration of the enzyme reaction step is 0.037 ng/. mu.L (10. mu.L)), 2. mu.L of saturated TK substrate-biotin solution (final concentration of the enzyme reaction step is 1. mu.M (10. mu.L)), together with 2. mu.L of ATP kinase buffer solution (final concentration of the enzyme reaction step is 3. mu.M (10. mu.L) for PYK2, JAK2, EGFR and PDGFR. beta.), final concentration of the enzyme reaction step is 1.6. mu.M (10. mu.L) for IGF-1R, and 1.5. mu.M (10. mu.L) for InsR), at room temperature for a specified time (30 minutes, 40 minutes, 50 minutes, 40 minutes, and 50 minutes for PYK2, JAK2, IGF-1R, InsR, EGFR and PDGFR. beta., respectively).
During the next enzymatic reaction step, 4. mu.L of the serially diluted small molecule compound to be tested (each standard compound described above), 2. mu.L of the TK substrate-biotin solution and 2. mu.L of the FAK kinase solution were first incubated, and then 2. mu.L of the ATP solution was added to start the enzymatic reaction. Next, enzyme buffer (from)kinEASETMTK kit), 5mM MgCl21mM DTT (dithiothreitol) and 25nM SEB (staphyloccal enterotoxin B) solution.
The detection reagent (5. mu.L of Eu) is added3+Cryptate-labeled TK-antibody and 5. mu.L of streptavidin-XL 665) were dissolved in the detection buffer (in the presence of EDTA), stirred and added to the reaction system. After 1 hour of the above incubation, the TR-FRET (time-resolved fluorescence energy transfer) signal, which is proportional to the phosphorylation level of the kinase, is detected with a microplate reader (BMG FS type). For each small molecule compound (corresponding F-19 standard molecule or drug intermediate molecule) tested, its IC for inhibition of FAK enzyme activity was determined by making a sigmoidal dose-response curve using GraphPad Prism Software (GraphPad Software, San Diego, Calif., USA)50(median inhibitory concentration) value.
In experiments with inhibition of FAK kinase activity in vitro, all standard compounds were evaluated using the HTRF method.
The specific detection results of the standard compound of the invention are shown in table 1.
TABLE 1 results of in vitro inhibition of FAK enzyme Activity by Standard Compounds
As can be seen from table 1 above, the compounds 27aa, 27ab, 28bb and 31bb of the present invention have significant inhibitory effects on the in vitro FAK enzyme activity. The excellent FAK in-vitro kinase activity inhibition capacity of the compounds lays a solid experimental foundation for the compounds to show excellent tumor growth inhibition effect after being prepared into tumor treatment medicines in future, and provides a more sufficient experimental basis for the compounds to be developed into radioactive medicines for early diagnosis and research of tumors in future.
Biodistribution experiment of F-18 radiopharmaceuticals in S180 tumor-bearing mice
2.1 animal model establishment
Under aseptic condition, disinfecting oxter skin of normal female Kunming mouse (18-22g) with alcohol, sucking well-grown S180 ascites, diluting with normal saline (2-3 times), inoculating to oxter subcutaneous tissue of mouse, and inoculating cell number (1-5) x 106. A size that is as long as the tumor size to a diameter of 0.5-0.8cm (about one week is required) can be used for the biological fractionAnd (5) performing a cloth experiment to obtain the S180 tumor mouse.
2.2 in vivo distribution experiments in animal radioactivity
The product of example 15-16 purified by HPLC18F]28ab、[18F]31bb、[18F]31bd、[18F]43 and [ 2 ]18F]44(10 μ Ci, dissolved in 0.1mL of physiological saline, containing 5% DMSO) was injected into S180 tumor mice by tail vein injection (18-22g, female, n ═ 5), the mice were sacrificed at 5min, 15min, 30min, 60min, 120min, decapitation, bleeding, brain, heart, liver, spleen, lung, kidney, muscle, bone, intestine, stomach, S180 tumor and tail were dissected, the wet weight of each organ was weighed and measured with γ -counter, uptake per tissue was finally expressed as% ID/g,% ID/g ═ ID/g ÷ 1%, where ID/g ═ radioactivity count of tissue (counts) ÷ tissue mass (mg), 1% ═ average of 1% ID per phase-tail radioactivity count/100.
2.3 discussion of results
TABLE 2. Compound [ 2 ]18F]Distribution of 28ab in female Kunming S180 tumor mice (18-22g)
The data in the table are the mean ± standard deviation of five measurements;
TABLE 3. Compound [ 2 ]18F]31bb distribution in female Kunming S180 tumor mice (18-22g)
The data in the table are the mean ± standard deviation of five measurements;
TABLE 4. Compound [ 2 ]18F]31bd in female Kunming S180 tumor mouse(18-22g) distribution in vivo
The data in the table are the mean ± standard deviation of five measurements.
TABLE 5. Compound [ 2 ]18F]43 distribution in female Kunming S180 tumor mice (18-22g)
The data in the table are the mean ± standard deviation of five measurements.
TABLE 6. Compound [ 2 ]18F]44 distribution in female Kunming S180 tumor mice (18-22g)
The data in the table are the mean ± standard deviation of five measurements.
As shown in tables 2-6, the results of the preliminary experiments indicate that the F-18 marker of the present invention shows a trend of increasing tumor uptake in S180 tumor-bearing mice relative to other organs in terms of biodistribution. And the absorption value of the tumor is higher than that of most other organs. The radioactive marker of the invention has ideal biological distribution in S180 tumor-bearing mice, and also provides more sufficient experimental basis for the early diagnosis and research of tumors by developing radioactive drugs for the compounds in the future.
3. Compound [ 2 ]19F]Pharmacodynamic study of 28ab in S180 murine tumor mouse model
3.1. Establishment of animal model
Under aseptic condition, disinfecting oxter skin of normal female Kunming mouse (18-22g) with alcohol, sucking well-grown S180 ascites, diluting with normal saline (2-3 times), inoculating to oxter subcutaneous tissue of mouse, and inoculating cell number (1-5) x 106。
3.2 animal groups
The test is provided with a negative control group, a positive control group and a treatment group. Wherein the treatment group is provided with a high dosage group, a middle dosage group and a low dosage group. The number of animals per group was 6. The animal models were randomly grouped the next day after establishment.
3.3 dosing regimens
3.4 drug configuration and route of administration
Compound [ 2 ]19F]28ab was dissolved in 5% Gelucire Glycerol laurate in sterile aqueous solution. The administration was performed orally with a gavage apparatus.
3.5 results of the experiment
Dosing was started after randomization, tumor size was measured and mouse body weight was weighed every 1-2 days. The tumor is approximated as a sphere and the Tumor Volume (TV) is calculated as: (4/3) π r ^ 3. From the measurement results, Relative Tumor Volume (RTV) was calculated, which is Vt/V0. Where V0 is the tumor volume measured at the time of caged administration (i.e., d0) and Vt is the tumor volume at each measurement. The evaluation index of the antitumor activity is relative tumor proliferation rate T/C (%): T/C% ═ TRTV/CRTV × 100%. TRTV: treatment group RTV; CRTV: negative control group RTV. The test period was 18 days.
Table 7. the Compound [ alpha ], [19F]Pharmacodynamic experiment result of 28ab in S180 murine tumor mouse model
From the results shown in Table 7 above, it is understood that the compound [ 2 ]19F]28ab has better tumor inhibition activity. Meanwhile, as shown in FIG. 6, the term "219F]The three dose groups of 28ab had tumor growth-inhibiting effects, with inhibition rates TGI (%) of 65.3%, 74.5%, 68.2% at the end of the day 18 trial, respectively. The inhibition rate was highest in the medium dose group (25.0mg/kg QOD), and the tumor growth was at the lowest growth rate all the time compared to the other groups, and there was also a case where the tumor volume was decreased. As shown in FIG. 7, the weight of the mice in the dose group (25.0mg/kg QOD) was not significantly reduced in view of the rate of increase in body weight, and was in a state of steady increase, indicating that it had less toxic and side effects in vivo and a higher inhibitory rate.
Claims (7)
1. A method for preparing a radionuclide F-18 labeled FAK-targeting compound,
the structure of the radionuclide F-18 labeled FAK targeting compound is shown as the following formula (IV), wherein R1is-Cl or-Br:
the preparation method is as follows, wherein R1is-Cl or-Br:
the method comprises the following specific steps:
E1) preparation of labeled precursor Compounds:
heating 4-fluoro-2-methoxynitrobenzene (compound 9) and piperazine (compound 13) in a1, 4-dioxane solution to 110-; catalytically hydrogenating the nitro group of compound 14 to provide compound 23; heating the compound 23, the compound 6 and p-toluenesulfonic acid in an organic solution to 100-120 ℃, stirring and reacting for 4-6h, and extracting with ethyl acetate to obtain a labeled precursor compound 29;
the compound 6 is synthesized by the following route, wherein R1is-Cl or-Br:
the method comprises the following specific steps:
A1) stirring 2-chloro-3-nitropyridine (compound 1) and methylsulfonylmethylamine with equal mass in an organic solvent at 0 ℃ to room temperature under an alkaline condition for reaction for 1-2h to obtain a compound 3;
A2) hydrogenating and reducing the nitro group of the compound 3 obtained in A1) into amino group under the condition of pressure catalysis at room temperature to obtain a compound 4;
A3) stirring and reacting the compound 4 obtained in the step A2) with the compound 5 at 80-90 ℃ for 4-6h under an alkaline condition to obtain a compound 6; the compound 5 is selected from 2,4, 5-trichloropyrimidine, 5-bromo-2, 4-dichloropyrimidine, 5-fluoro-2, 4-dichloropyrimidine or 5-methoxy-2, 4-dichloropyrimidine;
E2) radiolabeling:
using Kryptofix 2.2.2./, [ 2 ]18F]KF/K2CO3Complexing said labelled precursor compound 29 obtained in step E1)18F-nucleophilic substitution fluorination to obtain the F-18 labeled targeting FAK compound with the structure shown in the formula (IV).
2. The method according to claim 1, characterized in that step a1) comprises in particular the steps of: cooling 300mL DMF solution containing 183.4mmol of methylsulfonylmethylamine to 0 ℃ in ice bath, adding 220mmol of sodium hydride in batches, stirring at 0 ℃ for 1h, adding 126.5mmol of 2-chloro-3-nitropyridine, slowly heating to room temperature, and continuing to stir for 5 h; after the reaction is finished, pouring DMF into 1L of water, and then extracting for 3 times by using 300mL of ethyl acetate; the ethyl acetate layers were combined, dried over anhydrous sodium sulfate, filtered, concentrated by rotary evaporation, and separated by silica gel column chromatography using petroleum ether/ethyl acetate (10/1-3/1) to give compound 3.
3. The method according to claim 2, characterized in that step a2) comprises in particular the steps of: adding 43.3mmol of compound 3 in 200mL of methanol solution in a high-pressure reaction kettle at room temperature, adding 0.1equiv of 10% palladium-carbon, introducing hydrogen to 10bar, and reacting for 2h at room temperature; palladium carbon is filtered by diatomite, and the filtrate is evaporated and concentrated to obtain a compound 4.
4. The method according to claim 3, characterized in that step A3) comprises in particular the steps of: to a solution of 24.8mmol of Compound 4 in 100mL of DMF was added 29.6mmol of 2,4, 5-trichloropyrimidine and 37.2mmol of K2CO3Stirring the mixture for 5 hours at 90 ℃; after the reaction is finished, cooling to room temperature, pouring DMF into 500mL of water, and then extracting for 3 times by using 300mL of ethyl acetate; the ethyl acetate layers were combined, dried over anhydrous sodium sulfate, filtered, concentrated by rotary evaporation, and separated by silica gel column chromatography using petroleum ether/ethyl acetate 10/1 to 3/1 to give compound 6 a.
5. The process according to claim 1, wherein the preparation of compound 14 in step E1) comprises in particular the following steps: adding 70.0mmol of piperazine (compound 13) into a solution of 58.4mmol of 4-fluoro-2-methoxynitrobenzene (compound 9) in 300mL of 1, 4-dioxane, heating to 120 ℃, and stirring for 2 h; the reaction mixture was concentrated by rotary evaporation and separated by silica gel column chromatography using dichloromethane/methanol 20/1 to 5/1, whereby compound 14 was obtained.
6. The process according to any one of claims 4 or 5, characterized in that the preparation of compound 29 in step E1) comprises in particular the following steps: adding 4.2mmol of compound 23 and p-3.4 mmol of toluenesulfonic acid into 50mL of DMF solution of 2.8mmol of compound 6a, heating to 110 ℃, and stirring for 5 h; after the reaction is finished, pouring the reaction solution into 200mL of water, and then extracting for 3 times by using 50mL of ethyl acetate; the ethyl acetate layers were combined, dried over anhydrous sodium sulfate, filtered, and the concentrated filtrate was rotary-evaporated, and separated by silica gel column chromatography using dichloromethane/methanol from 20/1 to 5/1, to give compound 29.
7. The method according to any one of claims 1 or 6, characterized in that step E2) comprises in particular the steps of:
15mg of Kryptofix 222 was dissolved in 0.7mL of anhydrous acetonitrile, 1mg of K2CO3Dissolving in 0.3mL water, and mixing to obtain 1.0mL Kryptofix 222/K2CO3An eluent; capturing on QMA column with the eluate18F-Leaching into a reaction flask, and adding N at 100 DEG C2Blowing the solvent in the reaction bottle to dry, then adding 0.5mL of anhydrous acetonitrile into the solvent, blowing the solvent to dry again, and repeating the process for three times to ensure that the water in the reaction bottle is fully removed; rapidly adding 0.3mL of anhydrous acetonitrile solution of 4mg of 1, 2-bis (methylphenoxyethane) into the reaction bottle, sealing, and reacting for 10min at 110 ℃; after the reaction is finished, acetonitrile and water are used as mobile phases with the ratio of 1:1 to carry out radio-HPLC separation and purification, the flow rate is 4mL/min, the wavelength is 254nm, a C18 reversed phase semi-preparation column is adopted, and the product is 2-, [ product ] 2- ]18F]The retention time of fluoroethyl tosylate was 12 minutes;
2- [18F ] of the product of the previous step]HPLC receiver of fluoroethyl tosylate was collected in a 100mL sterile vial and 50mL water was added; the diluted product solution was loaded onto a Sep-Pak C-18 column, N2Air flow drying the Sep-Pak C-18 small column, eluting a product on the Sep-Pak C-18 column into a sterile vial by using 3mL of diethyl ether, and drying by using nitrogen flow at 40 ℃; adding 0.4mL acetonitrile solution of 4mg of compound 29, adding 1mg of anhydrous potassium carbonate, uniformly mixing, and reacting for 20 minutes at 120 ℃; the product was liquid phase separated through a semi-preparative column to give the F-18 labelled radioactive compound.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010157272.8A CN111233834B (en) | 2020-03-09 | 2020-03-09 | FAK-targeting compound and markers thereof, and preparation methods and applications of FAK-targeting compound and markers |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010157272.8A CN111233834B (en) | 2020-03-09 | 2020-03-09 | FAK-targeting compound and markers thereof, and preparation methods and applications of FAK-targeting compound and markers |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111233834A CN111233834A (en) | 2020-06-05 |
CN111233834B true CN111233834B (en) | 2021-08-31 |
Family
ID=70878523
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010157272.8A Expired - Fee Related CN111233834B (en) | 2020-03-09 | 2020-03-09 | FAK-targeting compound and markers thereof, and preparation methods and applications of FAK-targeting compound and markers |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111233834B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114716385B (en) * | 2022-04-08 | 2024-03-12 | 北京师范大学 | Compound of targeted focal adhesion kinase, preparation method and application |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101679264A (en) * | 2007-03-16 | 2010-03-24 | 斯克里普斯研究学院 | inhibitors of focal adhesion kinase |
CN101921236A (en) * | 2003-03-14 | 2010-12-22 | 诺瓦提斯公司 | Can be used for treating 2 of neoplastic disease, inflammatory and disorder of immune system, 4-two (phenylamino) pyrimidine |
CN106905303A (en) * | 2017-03-16 | 2017-06-30 | 北京师范大学 | The compound and its label and their preparation method and application of one class targeting FAK |
WO2019112344A1 (en) * | 2017-12-07 | 2019-06-13 | 주식회사 온코빅스 | Novel pyrimidine derivative having effect of inhibiting cancer cell growth and pharmaceutical composition containing same |
-
2020
- 2020-03-09 CN CN202010157272.8A patent/CN111233834B/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101921236A (en) * | 2003-03-14 | 2010-12-22 | 诺瓦提斯公司 | Can be used for treating 2 of neoplastic disease, inflammatory and disorder of immune system, 4-two (phenylamino) pyrimidine |
CN101679264A (en) * | 2007-03-16 | 2010-03-24 | 斯克里普斯研究学院 | inhibitors of focal adhesion kinase |
CN106905303A (en) * | 2017-03-16 | 2017-06-30 | 北京师范大学 | The compound and its label and their preparation method and application of one class targeting FAK |
WO2019112344A1 (en) * | 2017-12-07 | 2019-06-13 | 주식회사 온코빅스 | Novel pyrimidine derivative having effect of inhibiting cancer cell growth and pharmaceutical composition containing same |
Also Published As
Publication number | Publication date |
---|---|
CN111233834A (en) | 2020-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA017713B1 (en) | [f-18]-labeled l-glutamic acid, [f-18]-labeled l-glutamine, derivatives thereof and use thereof and processes for their preparation | |
CN101709060B (en) | F-triazole ring-polyethylene glycol-metronidazole compound and preparation method thereof | |
CN103059030B (en) | Pyrimidine compound with effect of adhesion kinase inhibition and preparation method and application thereof | |
CN112552272B (en) | Coumarin compound, preparation method and application thereof, and pharmaceutical composition | |
CN111233834B (en) | FAK-targeting compound and markers thereof, and preparation methods and applications of FAK-targeting compound and markers | |
CN106967058A (en) | A kind of preparation method for Wo Zhani | |
CN108947949B (en) | Anxiolytic deuterated compounds and medical application thereof | |
CN106905303A (en) | The compound and its label and their preparation method and application of one class targeting FAK | |
CN101723849B (en) | Novel 18F labeled amino acid derivatives, preparation method and application thereof in tumor imaging | |
CN109503590B (en) | 18F-PET/CT tracer with 7-deazaadenine base as mother nucleus and preparation method thereof | |
CN103254139A (en) | Novel <18>F marked 4-aminoquinazoline derivatives, and preparation methods and tumor PET development application thereof | |
CN101723850B (en) | Novel 18F labeled aromatic amino acids, preparation method and application thereof in tumor imaging | |
CN101768208B (en) | Novel 18F-labelled polypeptide, preparation method and application thereof in tumor imaging | |
CN114315795B (en) | 68 Ga-marked inhibitor radioactive probe for targeting fibroblast activation protein and preparation method thereof | |
CN112390760B (en) | FAK-targeting compound and preparation method and application thereof | |
CN116120239A (en) | Aromatic six-membered cycloimidazole derivative, and preparation method and application thereof | |
Chen et al. | Synthesis and evaluation of novel F-18 labeled 4-aminoquinazoline derivatives: Potential PET imaging agents for tumor detection | |
CN116082110B (en) | The method comprises the following steps of 11 C-labeled targeted anaplastic lymphoma kinase ALK mutant molecular probe and application thereof | |
CN108358958B (en) | Intermediate, intermediate synthesis method and application | |
WO2016097339A1 (en) | Labelled coumarin derivatives | |
CN110577478A (en) | Positron probe and preparation method and application thereof | |
CN106084004B (en) | 18F click-labeled transferrin receptor targeting polypeptide T7 as well as preparation method and application thereof | |
CN114805109B (en) | Efficient preparation method of fluoro [18F ] sand fenamide and PET imaging agent application | |
CN114671862B (en) | 18F-labeled radioactive tracer and preparation method thereof | |
EP4088745A1 (en) | Compound for the diagnosis of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210831 |